Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

7.8K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
7.8K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

2.9K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
2.9K
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

4.8K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
4.8K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

1.1K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

776
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
776

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peripheral Sympathetic Sprouting Drives Neuropathic Pain via Spinal Microglial P2Y12 Activation in a Rat Spinal Nerve Ligation Model.

Journal of pain research·2026
Same author

Managing street-tree health under rapid urbanization: Relative roles of street context and root-zone conditions in a subtropical city.

Journal of environmental management·2026
Same author

Engineering of Donor-Acceptor Nanodomains in Zn-Salen COFs Enhances Efficient Coupling Photoredox of Oxygen and Indoline.

Angewandte Chemie (International ed. in English)·2026
Same author

Mechanically Enhanced, Antibacterial, and Double-Network Hydrogel Flexible Sensors for Sleep Apnea Monitoring.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Soft matter-engineered pH-responsive hydrogels for encapsulation, protection, and controlled intestinal release of probiotics (Lacticaseibacillus paracasei YWC-01).

Food chemistry·2026
Same author

Population Pharmacokinetic/Pharmacodynamic Modeling of Volagidemab, a Glucagon Receptor Antagonist, in Healthy Chinese and US Subjects Following Single Subcutaneous Administration.

Pharmaceutical research·2026

Related Experiment Video

Updated: Mar 5, 2026

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique
07:35

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Published on: January 26, 2024

2.3K

Insulin and Glucagon: Partners for Life.

Jens Juul Holst1, William Holland2, Jesper Gromada3

  • 1Novo Nordisk Foundation Center for Basic Metabolic Research and Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark.

Endocrinology
|March 22, 2017
PubMed
Summary

Glucagon blockade shows therapeutic potential for diabetes treatment. However, effective glucagon antagonism requires sufficient basal insulin levels for optimal efficacy in patients.

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

96.0K
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

72.2K

Related Experiment Videos

Last Updated: Mar 5, 2026

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique
07:35

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Published on: January 26, 2024

2.3K
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

96.0K
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

72.2K

Area of Science:

  • Endocrinology and Metabolism
  • Diabetes Research
  • Hormone Signaling

Background:

  • Glucagon plays a critical role in glucose homeostasis and its dysregulation is central to diabetes pathogenesis.
  • Targeting the glucagon pathway is a promising strategy for diabetes treatment, but its efficacy is debated.
  • Previous research highlighted the complex interplay between insulin and glucagon in metabolic control.

Purpose of the Study:

  • To summarize the consensus reached at the European Association for the Study of Diabetes Hagedorn Workshop regarding glucagon antagonism in diabetes.
  • To elucidate the necessity of basal insulin for the therapeutic benefit of glucagon blockade.
  • To review experimental findings supporting the role of insulin in glucagon receptor antagonism.

Main Methods:

  • Discussion and consensus-building among leaders in glucagon biology at a workshop.
  • Review of experimental data from glucagon receptor-deficient mice.
  • Studies involving streptozotocin-induced and diphtheria toxin-induced pancreatic beta cell ablation in mice.

Main Results:

  • A consensus was reached emphasizing the critical need for basal insulin to enable glucagon blockade's therapeutic effects.
  • Studies using glucagon receptor-deficient mice with beta cell loss demonstrated key insights into this interaction.
  • Experimental evidence supports that glucagon antagonism is most effective when adequate basal insulin is present.

Conclusions:

  • Agents antagonizing glucagon offer significant potential for managing diabetes.
  • Therapeutic efficacy of glucagon blockade is contingent upon maintaining sufficient basal insulin levels.
  • Future diabetes therapies targeting glucagon must consider the essential role of basal insulin.